395 related articles for article (PubMed ID: 27559961)
1. Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study.
Nylén H; Habtewold A; Makonnen E; Yimer G; Bertilsson L; Burhenne J; Diczfalusy U; Aklillu E
Medicine (Baltimore); 2016 Aug; 95(34):e4631. PubMed ID: 27559961
[TBL] [Abstract][Full Text] [Related]
2. Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
Mugusi S; Ngaimisi E; Janabi M; Mugusi F; Minzi O; Aris E; Bakari M; Bertilsson L; Burhenne J; Sandstrom E; Aklillu E
Eur J Clin Pharmacol; 2018 Nov; 74(11):1405-1415. PubMed ID: 30003275
[TBL] [Abstract][Full Text] [Related]
3. Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients.
Aklillu E; Zumla A; Habtewold A; Amogne W; Makonnen E; Yimer G; Burhenne J; Diczfalusy U
Br J Pharmacol; 2021 Aug; 178(16):3294-3308. PubMed ID: 33155675
[TBL] [Abstract][Full Text] [Related]
4. Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO).
Wohl DA; Orkin C; Doroana M; Pilotto JH; Sungkanuparph S; Yeni P; Vanveggel S; Deckx H; Boven K
Antivir Ther; 2014; 19(2):191-200. PubMed ID: 24430534
[TBL] [Abstract][Full Text] [Related]
5. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.
Mukonzo JK; Okwera A; Nakasujja N; Luzze H; Sebuwufu D; Ogwal-Okeng J; Waako P; Gustafsson LL; Aklillu E
BMC Infect Dis; 2013 Jun; 13():261. PubMed ID: 23734829
[TBL] [Abstract][Full Text] [Related]
6. Higher serum 25-hydroxyvitamin D concentrations are associated with active pulmonary tuberculosis in hospitalised HIV infected patients in a low income tropical setting: a cross sectional study.
Musarurwa C; Zijenah LS; Mhandire DZ; Bandason T; Mhandire K; Chipiti MM; Munjoma MW; Mujaji WB
BMC Pulm Med; 2018 May; 18(1):67. PubMed ID: 29739378
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.
Habtewold A; Aklillu E; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Owen JS; Burhenne J
J Clin Pharmacol; 2016 Dec; 56(12):1538-1549. PubMed ID: 27125860
[TBL] [Abstract][Full Text] [Related]
8. Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.
Habtewold A; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Burhenne J; Aklillu E
Pharmacogenomics; 2015; 16(10):1047-64. PubMed ID: 25831219
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.
Yimer G; Ueda N; Habtewold A; Amogne W; Suda A; Riedel KD; Burhenne J; Aderaye G; Lindquist L; Makonnen E; Aklillu E
PLoS One; 2011; 6(12):e27810. PubMed ID: 22162992
[TBL] [Abstract][Full Text] [Related]
10. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D.
Brown TT; McComsey GA
Antivir Ther; 2010; 15(3):425-9. PubMed ID: 20516561
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
[TBL] [Abstract][Full Text] [Related]
12. Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations.
Mugusi S; Habtewold A; Ngaimisi E; Amogne W; Yimer G; Minzi O; Makonnen E; Sudfeld C; Burhenne J; Aklillu E
Front Pharmacol; 2020; 11():26. PubMed ID: 32116703
[TBL] [Abstract][Full Text] [Related]
13. Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old.
Kwara A; Yang H; Antwi S; Enimil A; Gillani FS; Dompreh A; Ortsin A; Opoku T; Bosomtwe D; Sarfo A; Wiesner L; Norman J; Alghamdi WA; Langaee T; Peloquin CA; Court MH; Greenblatt DJ
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397066
[TBL] [Abstract][Full Text] [Related]
14. Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy.
Padmapriyadarsini C; Bhavani PK; Tang A; Kumar H; Ponnuraja C; Narendran G; Hannah E; Ramesh C; Chandrasekar C; Wanke C; Swaminathan S
Int J Infect Dis; 2013 Dec; 17(12):e1154-9. PubMed ID: 24120216
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment.
Ngaimisi E; Minzi O; Mugusi S; Sasi P; Riedel KD; Suda A; Ueda N; Bakari M; Janabi M; Mugusi F; Bertilsson L; Burhenne J; Aklillu E; Diczfalusy U
J Antimicrob Chemother; 2014 Dec; 69(12):3311-9. PubMed ID: 25096076
[TBL] [Abstract][Full Text] [Related]
16. Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.
Naidoo A; Chirehwa M; McIlleron H; Naidoo K; Essack S; Yende-Zuma N; Kimba-Phongi E; Adamson J; Govender K; Padayatchi N; Denti P
J Antimicrob Chemother; 2017 May; 72(5):1441-1449. PubMed ID: 28175315
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D3 supplementation in HIV infection: effectiveness and associations with antiretroviral therapy.
Coelho L; Cardoso SW; Luz PM; Hoffman RM; Mendonça L; Veloso VG; Currier JS; Grinsztejn B; Lake JE
Nutr J; 2015 Aug; 14():81. PubMed ID: 26283663
[TBL] [Abstract][Full Text] [Related]
18. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM
Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067
[TBL] [Abstract][Full Text] [Related]
19. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1.
Patel A; Patel K; Patel J; Shah N; Patel B; Rani S
J Acquir Immune Defic Syndr; 2004 Sep; 37(1):1166-9. PubMed ID: 15319677
[TBL] [Abstract][Full Text] [Related]
20. CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.
Mukonzo JK; Nanzigu S; Waako P; Ogwal-Okeng J; Gustafson LL; Aklillu E
Pharmacogenomics; 2014 Aug; 15(11):1423-35. PubMed ID: 25303294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]